PM
AVEO

Prosight Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Prosight Management’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-7,010
Closed -$158K – 39
2018
Q2 		$158K Buy
+7,010
New +$166K 0.12% 31

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DVC
Deer VI & Co Larchmont, New York $2.23M AUM 9.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Prosight Management's AVEO Position: Q3 2018 in Review

Prosight Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q3 2018, closing a stake of 14,907 shares — an estimated $337K sold.

Prosight Management first reported a position in AVEO in Q4 2017 and held it in 3 quarters. The position peaked at $3.03M in Q1 2018. 101 funds tracked by Wall St. Rank hold AVEO as of Q3 2018.

  • Prosight Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Prosight Management sold 14,907 AVEO Pharmaceuticals, Inc. shares in Q3 2018, an estimated $337K.
  • Prosight Management first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2017 and held it in 3 quarters.
  • Prosight Management's AVEO Pharmaceuticals, Inc. position peaked at $3.03M in Q1 2018.
  • 101 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q3 2018.

Based on Prosight Management's 13F filing for Q3 2018, filed 15 Nov 2018.